Anti-vegf protein compositions and methods for producing the same
US-2024294606-A1 · Sep 5, 2024 · US
This page is not indexed by search engines while we improve data quality.
Johnson Amy patents
Johnson Amy is listed as an inventor on 27 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Johnson Amy |
| Total patents | 27 |
| First publication | Dec 17, 2015 |
| Latest publication | Sep 5, 2024 |
Notable patents
Publications ranked by popularity score, then publication date.
Anti-VEGF protein compositions and methods for producing the same
US-12012445-B2 · Jun 18, 2024 · US
Anti-vegf protein compositions and methods for producing the same
US-2023357357-A1 · Nov 9, 2023 · US
Bioreactor for antibody production
US-2023332084-A1 · Oct 19, 2023 · US
Anti-VEGF protein compositions and methods for producing the same
US-11732025-B2 · Aug 22, 2023 · US
Anti-vegf protein compositions and methods for producing the same
US-2023119662-A1 · Apr 20, 2023 · US
Anti-vegf protein compositions and methods for producing the same
US-2023068199-A1 · Mar 2, 2023 · US
Vegf mini-traps and method of use thereof
US-2023063116-A1 · Mar 2, 2023 · US
Anti-VEGF protein compositions and methods for producing the same
US-11548932-B2 · Jan 10, 2023 · US
Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
US-11535663-B2 · Dec 27, 2022 · US
Recent patents
Latest publications not already listed above.
Anti-vegf protein compositions and methods for producing the same
US-2022389081-A1 · Dec 8, 2022 · US
Anti-VEGF protein compositions and methods for producing the same
US-11505594-B2 · Nov 22, 2022 · US
Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
US-11472861-B2 · Oct 18, 2022 · US
Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
US-2022127331-A1 · Apr 28, 2022 · US
Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
US-2022033471-A1 · Feb 3, 2022 · US
Cell culture process for making a glycoprotein
US-2021388407-A1 · Dec 16, 2021 · US
Cell culture process for making a glycoprotein
US-2021388408-A1 · Dec 16, 2021 · US
Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
US-11104715-B2 · Aug 31, 2021 · US
Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
US-2021206832-A1 · Jul 8, 2021 · US
Cell culture process for making a glycoprotein
US-2020255880-A1 · Aug 13, 2020 · US
Cell culture process for making a glycoprotein
US-2020131554-A1 · Apr 30, 2020 · US
Treatment of cancer using anti-cd19 chimeric antigen receptor
US-2019388471-A1 · Dec 26, 2019 · US
Treatment of cancer using anti-CD19 Chimeric Antigen Receptor
US-10357514-B2 · Jul 23, 2019 · US
Cell culture process for making a glycoprotein
US-2019010531-A1 · Jan 10, 2019 · US
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
US-2018140602-A1 · May 24, 2018 · US
Biomarkers of bruton tyrosine kinase inhibitor resistance
US-2017298446-A1 · Oct 19, 2017 · US
Biomarker for predicting response of cll to treatment with a btk inhibitor
US-2015361504-A1 · Dec 17, 2015 · US
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Regeneron Pharma | 22 |
| Novartis Ag | 3 |
| Univ Pennsylvania | 3 |
| Regeneran Pharmaceuticals Inc | 3 |
| Pharmacyclics Llc | 1 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| C12N2500/32 | 21 |
| C07K14/71 | 21 |
| C12N15/85 | 20 |
| C12N2510/02 | 20 |
| C12N5/0018 | 20 |